07:00 , Jul 20, 2015 |  BC Week In Review  |  Financial News

Courtagen Life Sciences completes venture financing

Courtagen Life Sciences Inc., Woburn, Mass.   Business: Proteomics, Genomics   Date completed: 2015-07-15   Type: Venture financing   Raised: $20 million   Investors: Harbor Light Capital Partners; Adler; Bunker Hill Capital; First Analysis; high net worth investors   ...
07:00 , Jun 12, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Pre-mRNA processing factor 6 (PRPF6) Mouse and cell culture studies suggest inhibiting PRPF6 signaling could...
07:00 , Aug 23, 2012 |  BC Innovations  |  Targets & Mechanisms

CDK8 inhibitor: Senex's best thing

Chemotherapy is used to treat virtually every tumor type, but the drugs can blunt their own efficacy by inducing paracrine activity. Now, an international team led by Senex Biotechnology Inc. has mouse data showing that...
08:00 , Jan 2, 2012 |  BioCentury  |  Strategy

Ultra-rarified heir

Alexion Pharmaceuticals Inc. will have to wait three years to find out whether its purchase of Enobia Pharma Inc. for $610 million up front will provide a Soliris-like winner in ultra-Orphan metabolic bone diseases. Alexion...
07:00 , Sep 30, 2010 |  BC Innovations  |  Cover Story

Hsp90 JAK-hammer

Researchers at Memorial Sloan-Kettering Cancer Center and the Dana-Farber Cancer Institutehave found a mechanistic link between janus kinase-2 and heat shock protein 90 that opens up the possibility of using inhibitors of the latter in...
07:00 , Oct 2, 2006 |  BioCentury  |  Finance

4th Quarter Stock Preview: Pray for a 4-peat

Biotech financing got off to a brisk start this year, but has slowed since June, particularly in the U.S. At the same time, biotech stocks have lagged the rest of the market. But with valuations...
07:00 , Jul 3, 2006 |  BioCentury  |  Finance

3rd Quarter Stock Preview: Wanted: Inflows

The convergence of negative milestones and dour overall market conditions led mutual fund dollars to flee speculative growth stocks, including biotech, last quarter. The results weren't pretty: money flows were negative in healthcare/biotech mutual funds...
07:00 , Oct 11, 2004 |  BC Week In Review  |  Company News

Millennium management update

Millennium Pharmaceuticals Inc. (MLNM), Cambridge, Mass.   Business: Cancer, Cardiovascular, Inflammation   Hired: Laurie Keating as SVP, general counsel and secretary, formerly EVP of operations and finance at Hydra Biosciences Inc.; Lisa Adler as VP of...
08:00 , Dec 3, 2001 |  BC Week In Review  |  Company News

Syrrx management update

Syrrx Inc., San Diego, Calif.   Business: Proteomics, Computational chemistry/biology   Hired: William Ettouati as chief business officer, formerly VP of business development at Aurora Biosciences Corp.; and Carolyn Adler as VP of intellectual property and...
07:00 , Apr 7, 1997 |  BioCentury  |  Politics, Policy & Law

PTO to pull trigger on gene fragments

WASHINGTON - The Patent and Trademark Office is poised to approve patents for fragment gene sequences, according to John Doll, director of the PTO's biotechnology patent examining group. Doll told BioCentury last week that the...